A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)

Exclusion Criteria

• •Have a personal history of any of the following conditions: presyncope or syncope of either unexplained or cardiovascular etiology, ventricular arrhythmia (including but not limited to ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. Exception: Participants with controlled atrial fibrillation for \>30 days prior to study treatment are eligible.
• •Parts A, B, D and E: Have central nervous system (CNS) metastasis with development of associated neurological changes 14 days prior to receiving study drug.
• •Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix or breast), unless in complete remission with no therapy for a minimum of 3 years.
• •Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 3 to 4 months after the last dose of trial treatment (as appropriate).
• •Have active bacterial, fungal, and/or known viral infection (for example, human immunodeficiency virus \[HIV\] antibodies, hepatitis B surface antigen \[HBSAg\], or hepatitis C antibodies). Screening is not required for enrollment.
• •Parts A, B, C, and E: Have QTc interval of \> 470 millisecond (msec) on screening electrocardiogram (ECG). Part D participants have QTc interval of \>450msec on screening ECG.
• •History or evidence of cardiovascular risk including any of the following:
• •* History of acute coronary syndromes (including myocardial infarction and angina), coronary angioplasty, or stenting within 6 months prior to enrollment.
• •* History or evidence of current ≥Class II congestive heart failure as defined by New York Heart Association.
• •* Treatment refractory hypertension defined as a blood pressure of systolic \>140 millimeter of mercury (mmHg) and/or diastolic \>90 mmHg which cannot be controlled by antihypertensive therapy.
• •* Participants with intracardiac defibrillators.
• •History or evidence of CNS disease. Radiographic screening of all participants without history of CNS metastasis is required.
• •Radiographically documented evidence of major vessel invasion or encasement by cancer.
• •Uncontrolled thromboembolic or hemorrhagic disorders.
• •Participants receiving daily treatment with aspirin \>325mg/day or other known inhibitors of platelet function.
• •History of gross hemoptysis within 2 months of study entry.
• •Evidence of nonhealing wounds, ulcers, or bone fractures within 28 days prior to study entry.
• •Undergone major surgery within 28 days prior to first dose of study drug or have subcutaneous venous access device placement within 7 days prior to first dose.
• •Have insulin-dependent diabetes mellitus or a history of gestational diabetes mellitus.
• •Received prior monoclonal antibody (mAb) within 4 weeks prior to study.
• •Has active autoimmune disease that has required treatment in the past 2 years.
• •Has history of interstitial lung disease or pneumonitis.